Kezar Life Sciences, Inc. (KZR) Free Cash Flow (2017 - 2026)

Kezar Life Sciences has reported Free Cash Flow for 10 years, with the latest figure at -$7.4 million in Q1 2026.

• Quarterly Free Cash Flow rose 56.71% year-over-year to -$7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.0 million (up 38.71% YoY) and the FY2025 annual result came in at -$51.8 million, up 30.25% from the prior year.
• Free Cash Flow rose to -$7.4 million in Q1 2026 per KZR's latest filing, from -$12.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$7.4 million in Q1 2026 and troughed at -$22.9 million in Q1 2024.
• A 5-year average of -$16.3 million and a median of -$17.0 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2026: Free Cash Flow slumped 65.95% in 2023, then soared 56.71% in 2026.
• Over 5 years, Free Cash Flow stood at -$17.4 million in 2022, then fell by 9.21% to -$19.0 million in 2023, then increased by 11.3% to -$16.8 million in 2024, then increased by 28.95% to -$12.0 million in 2025, then surged by 37.76% to -$7.4 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$7.4 million, -$12.0 million, and -$9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.